Literature DB >> 11005502

Fournier's gangrene: changing face of the disease.

R J Yaghan1, T M Al-Jaberi, I Bani-Hani.   

Abstract

PURPOSE: Our experience with ten cases of Fournier's gangrene prompted us to review the related literature to highlight the current status of the disease.
METHODS: Data from ten patients with the diagnosis of Fournier's gangrene treated at our center from January 1997 until December 1998 were analyzed. These patients were treated by aggressive resuscitation, triple antibiotics, and urgent surgery. The English-language medical literature for the past 30 years was reviewed.
RESULTS: The epidemiologic features of our patients were similar to those reported in other recent studies. Mortality rate was 20 percent. Currently, the disease affects both genders and a wide range of ages, has a more insidious onset than in the past, and is not idiopathic. Associated systemic disorders (diabetes, alcoholism, and immunosuppression) are common. Perianal infection is the commonest cause and is associated with more moribund features.
CONCLUSION: The epidemiology of Fournier's gangrene is changing from its original description. Population aging worldwide--as a result of improving health care--and therefore the increasing prevalence of associated medical disorders may explain these changes. These factors may also explain the consistently high mortality rate during more recent years, masking any survival benefits from improved medical care. Better understanding of the pathophysiology has reduced the ratio of idiopathic cases to a minimum.

Entities:  

Mesh:

Year:  2000        PMID: 11005502     DOI: 10.1007/bf02237442

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  28 in total

1.  Role of mebo (moist exposed burn ointment) in the treatment of fournier's gangrene.

Authors:  M Al-Meshaan; M Abdul Hamid; T Quider; A Al-Sairafi; R Dham
Journal:  Ann Burns Fire Disasters       Date:  2008-03-31

2.  Fournier's ganrene in the HIV era.

Authors:  Peter Ngugi; George Magoha; Paul Nyaga
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

Review 3.  Fournier's gangrene and its emergency management.

Authors:  A Thwaini; A Khan; A Malik; J Cherian; J Barua; I Shergill; K Mammen
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

4.  A clinical case of Fournier's gangrene: imaging ultrasound.

Authors:  Marco Di Serafino; Chiara Gullotto; Chiara Gregorini; Claudia Nocentini
Journal:  J Ultrasound       Date:  2014-07-01

Review 5.  Rectal cancer and Fournier's gangrene - current knowledge and therapeutic options.

Authors:  Tomislav Bruketa; Matea Majerovic; Goran Augustin
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

6.  Outcomes of patients with Fournier's Gangrene: 12-year experience from a tertiary care referral center.

Authors:  Gaurav Garg; Vishwajeet Singh; Rahul Janak Sinha; Ashish Sharma; Siddharth Pandey; Ajay Aggarwal
Journal:  Turk J Urol       Date:  2019-12-01

Review 7.  Fournier's Gangrene: A Review and Outcome Comparison from 2009 to 2016.

Authors:  Mark Ferretti; Akhil A Saji; John Phillips
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-09-01       Impact factor: 4.730

8.  Fournier's gangrene: management and mortality predictors in a population based study.

Authors:  Mathew D Sorensen; John N Krieger; Frederick P Rivara; Matthew B Klein; Hunter Wessells
Journal:  J Urol       Date:  2009-10-17       Impact factor: 7.450

9.  Fournier's Gangrene after Open Hemorrhoidectomy without a Predisposing Factor: Report of a Case and Review of the Literature.

Authors:  Guldeniz Karadeniz Cakmak; Oktay Irkorucu; Bulent H Ucan; Kemal Karakaya
Journal:  Case Rep Gastroenterol       Date:  2009-05-15

10.  New insights into the epidemiology and etiology of Fournier's gangrene: a review of 33 patients.

Authors:  R Czymek; P Hildebrand; M Kleemann; U Roblick; M Hoffmann; T Jungbluth; C Bürk; H-P Bruch; P Kujath
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.